On May 19, 2017, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee (ACIP)’s updated recommendations on use of Trumenba meningococcal serogroup B vaccine.

The ACIP recommended routine use of MenB vaccines among persons aged ≥10 years who were at increased risk for serogroup B meningococcal disease (Category A recommendation), including persons who had persistent complement component deficiencies; persons who had anatomic or functional asplenia; microbiologists who routinely were exposed to isolates of Neisseria meningitidis; and persons identified to be at increased risk because of a serogroup B meningococcal disease outbreak.